222 related articles for article (PubMed ID: 33783349)
41. Collaborative study for the calibration of Ph. Eur. Heparin Sodium Biological Reference Preparation batch 4.
Lièvre V; Goujon N; Le Tallec D; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():167-183. PubMed ID: 34802510
[TBL] [Abstract][Full Text] [Related]
42. Collaborative study for the establishment of Ph. Eur. Biological Reference Preparation for Human tetanus immunoglobulin batch 2.
Stickings P; Tierney R; Hockley J; Rigsby P; Terao E
Pharmeur Bio Sci Notes; 2024; 2024():1-11. PubMed ID: 38252512
[TBL] [Abstract][Full Text] [Related]
43. An international collaborative study to establish the WHO 3rd International Standard for Thrombin: Communication from the ISTH SSC subcommittee on factor XIII and fibrinogen.
Locke M; Longstaff C; Rigsby P
J Thromb Haemost; 2021 Mar; 19(3):852-858. PubMed ID: 33650255
[TBL] [Abstract][Full Text] [Related]
44. Collaborative study for the recalibration of Ph. Eur. Heparin sodium BRP batch 3 for chromogenic potency assays.
Daas A; Rautmann G; Terao E
Pharmeur Bio Sci Notes; 2014; 2014():103-17. PubMed ID: 25655247
[TBL] [Abstract][Full Text] [Related]
45. Collaborative study for the establishment of Infliximab Biological Reference Preparation Batch 1.
Wadhwa M; Rigsby P; Behr-Gross ME
Pharmeur Bio Sci Notes; 2020; 2020():49-52. PubMed ID: 32459170
[TBL] [Abstract][Full Text] [Related]
46. Collaborative study for the establishment of the Ph. Eur. BRP for oral poliomyelitis vaccine (OPV) Batch 3 for use in the potency assay.
Buchheit KH; Daas A; Stalder J
Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):67-91. PubMed ID: 12448032
[TBL] [Abstract][Full Text] [Related]
47. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
Meager A; Das RG
J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
[TBL] [Abstract][Full Text] [Related]
48. New BRP for human plasma calibrated for coagulation factors V, VIII, XI and XIII - collaborative study for establishment of batches 1 and 2.
Bayer P; Daas A; Milne C
Pharmeur Bio Sci Notes; 2011 Nov; 2011(2):16-25. PubMed ID: 22225765
[TBL] [Abstract][Full Text] [Related]
49. Considerations on activity assay discrepancies in factor VIII and factor IX products.
Ovanesov MV; Jackson JW; Golding B; Lee TK
J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
[TBL] [Abstract][Full Text] [Related]
50. Establishment of European Pharmacopoeia (Ph. Eur.) Biological Reference Preparations (BRP) batch 2 for rDNA hepatitis B vaccine (method A and B).
Dobbelaer R; Daas A; Milne C
Pharmeuropa Bio; 2004 Jan; 2003(2):77-90. PubMed ID: 14960264
[TBL] [Abstract][Full Text] [Related]
51. Standardization of factor IX: standards for "purified" factor IX concentrates.
Lamb MA; Fricke WA; Rastogi SC
Thromb Haemost; 1991 Nov; 66(5):548-51. PubMed ID: 1803618
[TBL] [Abstract][Full Text] [Related]
52. A collaborative study to establish the 6th International Standard for factor VIII concentrate.
Raut S; Heath AB; Barrowcliffe TW
Thromb Haemost; 2001 Jun; 85(6):1071-8. PubMed ID: 11434687
[TBL] [Abstract][Full Text] [Related]
53. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
[TBL] [Abstract][Full Text] [Related]
54. Establishment of a biological reference preparation for hepatitis A vaccine (inactivated, non-adsorbed).
Stalder J; Costanzo A; Daas A; Rautmann G; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):15-29. PubMed ID: 20223187
[TBL] [Abstract][Full Text] [Related]
55. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
Ingerslev J; Jankowski MA; Weston SB; Charles LA;
J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
[TBL] [Abstract][Full Text] [Related]
56. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
57. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua.
Robinson MM; George LA; Carr ME; Samelson-Jones BJ; Arruda VR; Murphy JE; Rybin D; Rupon J; High KA; Tiefenbacher S
J Thromb Haemost; 2021 May; 19(5):1212-1218. PubMed ID: 33636038
[TBL] [Abstract][Full Text] [Related]
58. Calibration of replacement international standard and European Pharmacopoeia Biological Reference Preparation for Diphtheria Toxoid, Adsorbed.
Sesardic D; Winsnes R; Rigsby P; Gaines-Das R
Biologicals; 2001 Jun; 29(2):107-22. PubMed ID: 11580215
[TBL] [Abstract][Full Text] [Related]
59. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
Kang HN; Kim SN; Lee SH; Hong SH
Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
[TBL] [Abstract][Full Text] [Related]
60. Collaborative study for establishment of a global standard for the potency assay of human anti-D immunoglobulin.
Thorpe SJ; Sands D; Fox B; Schäffner G; Yu MW; Behr-Gross ME
Pharmeuropa Bio; 2004 Jan; 2003(2):9-26. PubMed ID: 14960260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
